Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
Clinical trial NCT03499353 · TERMINATED
Trial details
- NCT number
- NCT03499353
- Sponsor
- Pfizer
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-08-27
- Primary completion
- 2020-09-23
- Enrollment
- 61
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.